ClinicalTrials.gg
RecruitingNCT05550077OCT-ICASUpdated Sep 23, 2022

Optical Coherence Tomography for Intracranial Atherosclerotic Stenosis

An observational study in Intracranial Atherosclerosis, Optical Coherence Tomography and Plaque, Atherosclerotic, sponsored by jiaoliqun. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-23.

Sponsored by jiaoliqun · Observational

How we know

From the registry’s dates

  • Started Mar 2020; still recruiting 6 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Intracranial Arteriosclerosis with a site in China — 28 open to participants now, 28 under way, 2 of them phase 3. Intracranial Arteriosclerosis · China.

Planned enrollment
6th of 17
400 · median 300
Started
2020
with 1 other
Observational
17 of 44
12 open now
Primary completion
2026-12
later than 15 of 27 live
Registered
18th of 44
by date

Among the 44 studies in Intracranial Arteriosclerosis with a site in China, this one is the 6th largest by planned enrollment of the 17 observational ones that give a count, is one of 2 that started in 2020, is one of 17 observational ones, reaches primary completion later than 15 of the 27 other live ones, and was the 18th registered.

Intracranial Arteriosclerosis

103 studies on the registry are indexed under Intracranial Arteriosclerosis; 49 are open to participants now.

Browse Intracranial Arteriosclerosis studies →

Open to participants now

28 of the 44 studies in Intracranial Arteriosclerosis with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 29 Intracranial Arteriosclerosis studies recruiting now, 12 (41%) set no upper age limit and 1 (3%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Intracranial Arteriosclerosis with a site in China, or all of them as a file.
02

Study summary

To evaluate the clinical significance of optical coherence tomography (OCT) in interventional treatment of intracranial atherosclerotic stenosis (ICAS).

Read the detailed description

Stroke was the second leading cause of death worldwide and the leading cause of death in China in 2017. ICAS accounted for 10% to 15% of ischemic stroke in Western countries, and as much as 46.6%in Asia in 2009.

For patients with ICAS, the risk of stroke is highly related to the histopathology of atheromatous plaques. Therefore, characterizing the morphology and composition of plaques in ICAS may help to predict the risk of stroke occurrence and allow the adoption of preventive or therapeutic management to prevent such life-threatening events. OCT, with a resolution of 10μm, may provide more reliable information in characterizing atheromatous plagues.

This study aims to get a better insight into the value of OCT in evaluating the vessel wall structure and therefore guiding the interventional therapy of ICAS. In addition, the clinical and biological information will be included to achieve correlation analysis so as to get biomarkers subject to various plaque characteristics.

03

Conditions studied

  • Intracranial Atherosclerosis
  • Optical Coherence Tomography
  • Plaque, Atherosclerotic
  • Artery Stenosis
  • Ischemic Stroke

Keywords

  • Optical Coherence Tomography
  • Intravascular Imaging
  • Intracranial Atherosclerotic Stenosis
  • Percutaneous Transluminal Angioplasty and Stenting
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (aged over 18) with symptomatic ICAS (≥ 50%) will be enrolled.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic ICAS. Participants with ICAS with a (TIA) or stroke attributable to the territory of the stenotic artery were defined as symptomatic. A TIA was defined as a transient episode of neurological dysfunction (focal weakness or language disturbance, transient monocular blindness, or required assistance in walking) caused by focal brain or retinal ischaemia that lasted for at least 10 minutes but resolved within 24 hours
  • Stenotic degree ≥ 50%, measured by digital subtraction angiography
  • The stenosis must located in at least one major intracranial artery (internal carotid artery, vertebral artery, middle cerebral artery, or basilar artery)

Exclusion criteria

Exclusion Criteria:

  • Arteriovenous Malformation
  • Aneurysm
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Optical Coherence Tomography (OCT)

    OCT and other classical imaging evaluation such as Transcranial Color Doppler (TCCD) and High resolution-MRI will be performed. The tailored treatment (such as anti-thrombotic management, post-dilation, et al) will be considered when specific plaque characteristics (including but not limited to in situ thrombus formation, macrocacilfication, et al), were observed under OCT.

    Diagnostic Test: Optical Coherence Tomography · Procedure: Percutaneous transluminal angioplasty and stenting

  • Non-Optical Coherence Tomography (N-OCT)

    Classical imaging evaluation such as TCCD and High resolution-MRI will be performed, followed by standard percutaneous transluminal angioplasty and stenting.

    Procedure: Percutaneous transluminal angioplasty and stenting

Interventions

  • Diagnostic testOptical Coherence Tomography

    Intravascular evaluation for vessel wall structure of intracranial atherosclerotic stenosis by application of optical coherence tomography

  • ProcedurePercutaneous transluminal angioplasty and stenting

    Percutaneous transluminal angioplasty and stenting will be performed follow the standard or adjusted according to OCT evaluation.

06

What researchers measure

Primary outcomes

  1. Safety outcomes: short-term death or stroke

    We defined 'short-term' as the periprocedural period, or mean follow-up time less than or equal to three months after enrollment. Stroke was identified in the vascular territory of the stenosed vessel, either ischaemic or haemorrhagic. We defined death or stroke as a composite of death of any cause or non-fatal stroke of any type in any territory.

    Time frame: 30 days after enrollment

Secondary outcomes

  1. Death or stroke

    (long term; more than three months)

    Time frame: 1 year after enrollment

  2. Ipsilateral stroke

    (same territory as the index stenosis)

    Time frame: 1 year after enrollment

  3. Type of recurrent event

    (TIA, ischaemic stroke, haemorrhagic stroke)

    Time frame: 1 year after enrollment

  4. Death

    (long term; more than three months)

    Time frame: 1 year after enrollment

  5. Restenosis

    (≥ 50%) of the involved vessel documented by conventional cerebral angiography

    Time frame: 1 year after enrollment

  6. Dependency

    Modified Rankin Scale or equivalent

    Time frame: 1 year after enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2020 (actual). Primary completion is estimated for Dec 2026, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2022
First posted
Sep 22, 2022
StartActual
Mar 15, 2020
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2027
Last update
Sep 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05550077
Lead sponsor
jiaoliqun
Responsible party
jiaoliqun (Director, Department of Interventional Neuroradiology, Principal Investigator, Clinical Professor, Xuanwu Hospital, Beijing) — Sponsor-investigator
First posted
Sep 22, 2022
Start date
Mar 15, 2020
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 23, 2022

Study contacts

Liqun Jiao, Professor
Contact
liqunjiao@sina.cn
+8613911224991

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion